Sandra Strychor

1.1k total citations
41 papers, 833 citations indexed

About

Sandra Strychor is a scholar working on Oncology, Molecular Biology and Biomaterials. According to data from OpenAlex, Sandra Strychor has authored 41 papers receiving a total of 833 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 19 papers in Molecular Biology and 9 papers in Biomaterials. Recurrent topics in Sandra Strychor's work include Cancer therapeutics and mechanisms (13 papers), Neutropenia and Cancer Infections (11 papers) and Cancer Treatment and Pharmacology (10 papers). Sandra Strychor is often cited by papers focused on Cancer therapeutics and mechanisms (13 papers), Neutropenia and Cancer Infections (11 papers) and Cancer Treatment and Pharmacology (10 papers). Sandra Strychor collaborates with scholars based in United States, South Korea and Nigeria. Sandra Strychor's co-authors include William C. Zamboni, Beth A. Zamboni, Chandra P. Belani, Jay W. Pettegrew, Ramesh K. Ramanathan, Suresh S. Ramalingam, Julie L. Eiseman, Robert A. Parise, Kanagasabai Panchalingam and Jan H. Beumer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Sandra Strychor

41 papers receiving 820 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandra Strychor United States	18	359	328	235	124	106	41	833
How-Sung Lee Singapore	12	217 0.6×	324 1.0×	154 0.7×	121 1.0×	73 0.7×	17	823
Claude Dagenais Canada	10	545 1.5×	727 2.2×	136 0.6×	65 0.5×	90 0.8×	11	1.5k
Gérald Tuffin Switzerland	12	291 0.8×	191 0.6×	92 0.4×	63 0.5×	28 0.3×	15	684
Na Qu China	14	365 1.0×	92 0.3×	141 0.6×	94 0.8×	82 0.8×	56	754
Chunxi Wang China	18	558 1.6×	141 0.4×	133 0.6×	129 1.0×	193 1.8×	58	1.1k
Xiaoyan Yu China	17	477 1.3×	153 0.5×	135 0.6×	204 1.6×	71 0.7×	34	1.0k
Sarah Giacometti France	14	296 0.8×	259 0.8×	94 0.4×	95 0.8×	57 0.5×	25	690
Marcella Barbarino Italy	22	508 1.4×	252 0.8×	53 0.2×	54 0.4×	152 1.4×	35	1.0k
Susanne Häfner Germany	19	543 1.5×	184 0.6×	54 0.2×	66 0.5×	143 1.3×	38	1.0k
Stephanie M. Tortorella Australia	9	652 1.8×	163 0.5×	133 0.6×	123 1.0×	101 1.0×	12	1.1k

Countries citing papers authored by Sandra Strychor

Since Specialization

Citations

This map shows the geographic impact of Sandra Strychor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Strychor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Strychor more than expected).

Fields of papers citing papers by Sandra Strychor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Strychor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Strychor. The network helps show where Sandra Strychor may publish in the future.

Co-authorship network of co-authors of Sandra Strychor

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Strychor. A scholar is included among the top collaborators of Sandra Strychor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Strychor. Sandra Strychor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rodler, Eve T., Brenda F. Kurland, Melissa Griffin, et al.. (2016). Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer. Clinical Cancer Research. 22(12). 2855–2864. 69 indexed citations

Eads, Jennifer R., Jan H. Beumer, Lavinia Negrea, et al.. (2015). A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. Cancer Chemotherapy and Pharmacology. 77(2). 333–338. 7 indexed citations

Eiseman, Julie L., Jan H. Beumer, Lora H. Rigatti, et al.. (2014). Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews. Cancer Chemotherapy and Pharmacology. 75(1). 143–152. 12 indexed citations

Magge, Deepa, Amer H. Zureikat, David L. Bartlett, et al.. (2013). A Phase I Trial of Isolated Hepatic Perfusion (IHP) Using 5-FU and Oxaliplatin in Patients with Unresectable Isolated Liver Metastases from Colorectal Cancer. Annals of Surgical Oncology. 20(7). 2180–2187. 6 indexed citations

Wu, Huali, Ramesh K. Ramanathan, Beth A. Zamboni, et al.. (2011). Population Pharmacokinetics of Pegylated Liposomal CKD‐602 (S‐CKD602) in Patients With Advanced Malignancies. The Journal of Clinical Pharmacology. 52(2). 180–194. 30 indexed citations

Zamboni, William C., Julie L. Eiseman, Sandra Strychor, et al.. (2010). Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models. Journal of Liposome Research. 21(1). 70–80. 23 indexed citations

Zamboni, William C., Sandra Strychor, Beth A. Zamboni, et al.. (2010). Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. Journal of Liposome Research. 21(2). 158–165. 38 indexed citations

Ramalingam, Suresh S., R. Donald Harvey, Nabil F. Saba, et al.. (2010). Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer. 116(16). 3903–3909. 32 indexed citations

Strychor, Sandra, et al.. (2009). Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies. Clinical Pharmacology & Therapeutics. 86(5). 519–526. 33 indexed citations

10.

Zamboni, William C., Laura Jung, Sandra Strychor, et al.. (2008). Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice. Investigational New Drugs. 26(5). 399–406. 6 indexed citations

11.

Edwards, Robert P., et al.. (2007). Evaluation of body surface area (BSA) based dosing, age, and body composition as factors affecting the pharmacokinetic (PK) variability of STEALTH liposomal doxorubicin (Doxil). Molecular Cancer Therapeutics. 6. 8 indexed citations

12.

DeLoia, Julie A., et al.. (2007). Expression and activity of taxane-metobolizing enzymes in ovarian tumors. Gynecologic Oncology. 108(2). 355–360. 19 indexed citations

13.

Florian, Jeffry, William C. Zamboni, Julie L. Eiseman, et al.. (2006). A physiologically-based pharmacokinetic (PBPK) model of docetaxel in SCID mice bearing SKOV3 human ovarian cancer xenografts. Cancer Research. 66. 730–730. 1 indexed citations

14.

Strychor, Sandra, Julie L. Eiseman, Erin Joseph, et al.. (2006). Plasma, tissue and tumor disposition of STEALTH® liposomal CKD-602 (S-CKD602) and non-liposomal CKD-602, a camptothecin analogue, in mice bearing A375 human melanoma xenografts. Cancer Research. 66. 721–721. 3 indexed citations

15.

Akhavan, Ardavan, Georgi Guruli, Robert R. Bies, et al.. (2006). Endothelin Receptor A Blockade Enhances Taxane Effects in Prostate Cancer. Neoplasia. 8(9). 725–732. 37 indexed citations

16.

Zamboni, William C., Ramesh K. Ramanathan, Howard L. McLeod, et al.. (2006). Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Investigational New Drugs. 24(5). 393–401. 32 indexed citations

17.

Zamboni, William C., Douglas M. Potter, Ramesh K. Ramanathan, et al.. (2005). Allometric scaling of STEALTH® liposomal anticancer agents. Cancer Research. 65. 326–326. 4 indexed citations

18.

Ramanathan, Ramesh K., Sakkaraiappan Ramalingam, Merrill J. Egorin, et al.. (2004). Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Cancer Chemotherapy and Pharmacology. 55(4). 354–360. 13 indexed citations

19.

Jung, Laura, Ramesh K. Ramanathan, Merrill J. Egorin, et al.. (2004). Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 54(6). 487–496. 17 indexed citations

20.

Kanfer, J. N., Jay W. Pettegrew, John Moossy, et al.. (1991). Possible Enzymatic Causes for Elevated Phosphomonoesters in Alzheimer's Disease Brain Tissuea. Annals of the New York Academy of Sciences. 640(1). 118–121. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact